Similasan shortage — US supply status & alternatives

Similasan

—

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Similasan
Therapeutic category	Auto-created by FDA Drug Enforcement — Full Recall Database scraper
Controlled substance	No
Marketing-authorisation holders	Similasan Corporation, SISU INC., SIMILASAN AG

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇺🇸

United States

FDA MedWatch · 5h ago

High

Recalls official enforcement reports

🇺🇸

Similasan

Thea Pharma, Inc. · Apr 2026

Class IIdetails ↗

Verified timeline regulator events

🇺🇸 23 Apr 2026

high reported

Sources official regulators

🇺🇸

FDA MedWatch

verified 5h ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders3 registrations · 3 MA holders

Product	Strength	Form	Market	MA holder	Status
Similasan Earache Relief	10; 15; 12[hp_X]/10mL; [hp_X]/10mL; [hp_X]/10mL	solution	🇺🇸 US	Similasan Corporation	Active
Similasan Nasal Spray Liq	—	liquid	🇨🇦 CA	SISU INC.	Active
Similasan Eye Drops No2	—	liquid	🇨🇦 CA	SIMILASAN AG	Cancelled

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.